Mayo clinic study probes immune secrets of breast cancer drugs
NCT ID NCT04517838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects blood and tumor samples from 230 adults with HER2-positive breast cancer (stages I-IV) who are starting anti-HER2 drugs like trastuzumab. Researchers want to see how the immune system reacts to these treatments. The goal is to learn more, not to test a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?